PubMed:1436241 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PubMed/sourceid/1436241","sourcedb":"PubMed","sourceid":"1436241","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/1436241","text":"Cytokine (IFN-alpha, IFN-gamma, IL-1-alpha, TNF-alpha)-induced modulation of HLA cell surface expression in human breast cancer cell lines.\nCytokine-induced modulation of HLA expression on the cell surface of four human breast cancer cell lines was determined by continuous flow immunocytofluorometry with the aid of monoclonal antibodies directed to a non-polymorphic determinant of HLA class I and class II (DR) antigen. IFN-gamma and IFN-alpha were potent inducers of HLA class I in all examined cell lines, with decreasing inducibility as follows: BT-20, ZR-75-1, MCF-7 and MDA-MB-468 cells. HLA class II (DR) antigen was highly inducible by IFN-gamma in ZR-75-1 cells, followed by BT-20, MDA-MB-468 and MCF-7 cells. IFN-alpha increased the cell surface expression of DR antigen only in ZR-75-1 cells. IL-1-alpha induced a moderate level of HLA class I antigen in ZR-75-1, BT-20 and MDA-MB-468 cells, and HLA class II (DR) expression only in ZR-75-1 cells. This pattern of cell line inducibility by IL-1-alpha was similar to that induced by TNF-alpha. Differences in inducibility of HLA antigens on human breast cancer cell lines induced by different cytokines may reflect the differences in cytokine inducibility of the original tumor cells.","tracks":[{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":220,"end":233},"obj":"HP_0003002"},{"id":"T2","span":{"begin":220,"end":233},"obj":"HP_0100013"},{"id":"T3","span":{"begin":227,"end":233},"obj":"HP_0002664"},{"id":"T4","span":{"begin":1109,"end":1122},"obj":"HP_0003002"},{"id":"T5","span":{"begin":1109,"end":1122},"obj":"HP_0100013"},{"id":"T6","span":{"begin":1116,"end":1122},"obj":"HP_0002664"},{"id":"T7","span":{"begin":1234,"end":1239},"obj":"HP_0002664"}],"attributes":[{"subj":"T1","pred":"source","obj":"PubmedHPO"},{"subj":"T2","pred":"source","obj":"PubmedHPO"},{"subj":"T3","pred":"source","obj":"PubmedHPO"},{"subj":"T4","pred":"source","obj":"PubmedHPO"},{"subj":"T5","pred":"source","obj":"PubmedHPO"},{"subj":"T6","pred":"source","obj":"PubmedHPO"},{"subj":"T7","pred":"source","obj":"PubmedHPO"}]},{"project":"CoMAGC","denotations":[{"id":"T1","span":{"begin":909,"end":926},"obj":"Gene"},{"id":"E1","span":{"begin":927,"end":937},"obj":"Gene_expression"},{"id":"E2","span":{"begin":817,"end":824},"obj":"Positive_regulation"},{"id":"T2","span":{"begin":887,"end":897},"obj":"breast cancer"},{"id":"T3","span":{"begin":868,"end":875},"obj":"breast cancer"},{"id":"T4","span":{"begin":946,"end":953},"obj":"breast cancer"},{"id":"T5","span":{"begin":877,"end":882},"obj":"breast cancer"}],"relations":[{"id":"R1","pred":"themeOf","subj":"T1","obj":"E1"},{"id":"R2","pred":"themeOf","subj":"E1","obj":"E2"},{"id":"R3","pred":"CGE-increased","subj":"T1","obj":"T2"},{"id":"R4","pred":"CCS-unidentifiable","subj":"T1","obj":"T2"},{"id":"R5","pred":"PT-","subj":"T1","obj":"T2"},{"id":"R3","pred":"IGE-","subj":"T1","obj":"T2"}],"attributes":[{"subj":"T1","pred":"source","obj":"CoMAGC"},{"subj":"E1","pred":"source","obj":"CoMAGC"},{"subj":"E2","pred":"source","obj":"CoMAGC"},{"subj":"T2","pred":"source","obj":"CoMAGC"},{"subj":"T3","pred":"source","obj":"CoMAGC"},{"subj":"T4","pred":"source","obj":"CoMAGC"},{"subj":"T5","pred":"source","obj":"CoMAGC"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"PubmedHPO","color":"#ec93ea","default":true},{"id":"CoMAGC","color":"#93ecd3"}]}]}}